ACADIA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.1 USD | +0.67% |
|
-2.83% | -51.77% |
Financials (USD)
| Sales 2024 * | 954M | Sales 2025 * | 1.07B | Capitalization | 2.49B |
|---|---|---|---|---|---|
| Net income 2024 * | 101M | Net income 2025 * | 205M | EV / Sales 2024 * | 2.02 x |
| Net cash position 2024 * | 570M | Net cash position 2025 * | 786M | EV / Sales 2025 * | 1.6 x |
| P/E ratio 2024 * |
26.3
x | P/E ratio 2025 * |
13.2
x | Employees | 610 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on ACADIA Pharmaceuticals Inc.
More recommendations
More press releases
More news
| 1 day | +0.67% | ||
| 1 week | -2.83% | ||
| Current month | -9.63% | ||
| 1 month | -9.63% | ||
| 3 months | -37.11% | ||
| 6 months | -32.23% | ||
| Current year | -51.77% |
1 week
14.60
15.35
1 month
14.6017.58
Current year
14.6031.82
1 year
14.6033.99
3 years
12.2433.99
5 years
12.2458.72
10 years
12.2458.72
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Benir Ruano
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.73% | 1 M€ | -.--% | - | |
| 1.24% | 14 M€ | -5.07% | ||
| 0.26% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 15.1 | +0.67% | 1,342,832 |
| 24-05-30 | 15 | +2.60% | 1,133,505 |
| 24-05-29 | 14.62 | -3.11% | 1,388,763 |
| 24-05-28 | 15.09 | -0.72% | 1,059,072 |
| 24-05-24 | 15.2 | -2.19% | 1,520,224 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
15.1
USD
Average target price
27.16
USD
Spread / Average Target
+79.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.77% | 2.48B | |
| +43.36% | 58.06B | |
| -5.31% | 40.53B | |
| +37.52% | 38.99B | |
| +14.75% | 26.7B | |
| -12.56% | 26.56B | |
| -22.45% | 18.98B | |
| +0.04% | 12.17B | |
| +25.12% | 12B | |
| +26.04% | 11.92B |
- Stock Market
- Equities
- ACAD Stock
